PRNB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRNB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Principia Biopharma's Other Stockholders Equity for the quarter that ended in Jun. 2020 was $-0.00 Mil.
Principia Biopharma's quarterly Other Stockholders Equity declined from Dec. 2019 ($0.00 Mil) to Mar. 2020 ($-0.00 Mil) but then stayed the same from Mar. 2020 ($-0.00 Mil) to Jun. 2020 ($-0.00 Mil).
Principia Biopharma's annual Other Stockholders Equity stayed the same from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($0.00 Mil) but then declined from Dec. 2018 ($0.00 Mil) to Dec. 2019 ($0.00 Mil).
The historical data trend for Principia Biopharma's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Principia Biopharma Annual Data | |||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | |||||
Other Stockholders Equity | - | - | - | - |
Principia Biopharma Quarterly Data | |||||||||||||
Dec16 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Other Stockholders Equity | Get a 7-Day Free Trial | - | - | - | - | - |
Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity
Thank you for viewing the detailed overview of Principia Biopharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Stefani Wolff | officer: Chief Development Officer | C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Martin Babler | director, officer: President, CEO | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Dolca Thomas | officer: Chief Medical Officer | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Simeon George | director | 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428 |
Shawn Tomasello | director | C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Alan Colowick | director | C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063 |
Shao-lee Lin | director | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
David M Goldstein | officer: Chief Scientific Officer | C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 |
Roy C. Hardiman | officer: Chief Business Officer | C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085 |
Christopher Y Chai | officer: Chief Financial Officer | 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By Marketwired Marketwired • 08-18-2020
By PRNewswire PRNewswire • 01-27-2020
By Business Wire Business Wire • 08-17-2020
By Marketwired Marketwired • 12-30-2019
By Marketwired Marketwired • 01-07-2020
By Marketwired Marketwired • 01-09-2020
By [email protected] insider • 02-17-2020
By Marketwired Marketwired • 06-12-2020
By [email protected] insider • 08-21-2020
By Marketwired Marketwired • 06-23-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.